Analysis of PIK3CA mutations and PI3K signaling proteins as prognostic biomarkers for advanced gastric cancer

被引：0
|
作者：
Nishizuka, Satoshi S.
Ito, Chie
Kume, Kohei
Iwaya, Takeshi
Koeda, Keisuke
Sasaki, Akira
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4727
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer
    Ito, Chie
    Nishizuka, Satoshi S.
    Ishida, Kazuyuki
    Uesugi, Noriyuki
    Sugai, Tamotsu
    Tamura, Gen
    Koeda, Keisuke
    Sasaki, Akira
    JOURNAL OF SURGICAL RESEARCH, 2017, 212 : 195 - 204
  • [2] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Zhu, Yu-Fen
    Yu, Bao-Hua
    Li, Da-Li
    Ke, Hong-Lin
    Guo, Xian-Zhi
    Xiao, Xiu-Ying
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (28) : 3745 - 3751
  • [3] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Yu-Fen Zhu
    World Journal of Gastroenterology, 2012, (28) : 3745 - 3751
  • [4] Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
    Kubler, Kirsten
    Nardone, Agostina
    Anand, Shankara
    Gorvich, Daniel
    Droog, Marjolein
    Hermida-Prado, Francisco
    Akshi, Tara
    Feit, Avery S.
    Cohen, Gabriella
    Dackus, Gwen
    Pun, Matthew
    Kuang, Yanan
    Cha, Justin
    Miller, Mendy
    Gibson, William J.
    Paweletz, Cloud P.
    Van Allen, Eliezer M.
    van Leeuwen, Flora E.
    Nederlof, Petra
    Hollema, Harry
    Quang-De Nguyen
    Mourits, Marian J. E.
    Leshchiner, Ignaty
    Stewart, Chip
    Matulonis, Ursula A.
    Zwart, Wilbert
    Maruvka, Yosef E.
    Getz, Gad
    Jeselsohn, Rinath
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Vasan, N.
    Razavi, P.
    Johnson, J. L.
    Shao, H.
    Reznik, E.
    Smith, M. L.
    Sebra, R.
    Cantley, L. C.
    Scaltriti, M.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 1 - 1
  • [6] PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC
    Heavey, S.
    Davies, M. A.
    O'Byrne, K. J.
    Gately, K.
    LUNG CANCER, 2013, 79 : S3 - S3
  • [7] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [8] PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
    Janku, Filip
    Tsimberidou, Apostolia M.
    Garrido-Laguna, Ignacio
    Wang, Xuemei
    Luthra, Rajyalakshmi
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Moroney, John W.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Moulder, Stacy L.
    Fu, Siqing
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (03) : 558 - 565
  • [9] PIK3CA and PIK3R1 mutations in cancer: from the mechanism of activation to PI3K targeted therapies
    Rzepecka, Iwona K.
    Tysarowski, Andrzej
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [10] Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
    Fang, Wen-Liang
    Huang, Kuo-Hung
    Lan, Yuan-Tzu
    Lin, Chien-Hsing
    Chang, Shih-Ching
    Chen, Ming-Huang
    Chao, Yee
    Lin, Wen-Chang
    Lo, Su-Shun
    Li, Anna Fen-Yau
    Wu, Chew-Wun
    Chiou, Shih-Hwa
    Shyr, Yi-Ming
    ONCOTARGET, 2016, 7 (05) : 6201 - 6220
12345